Trial Profile
Effectiveness of erlotinib treatment in advanced KRAS mutation-negative lung adenocarcinoma patients: Results of a multicenter observational cohort study (MOTIVATE).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Dec 2015
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms MOTIVATE
- 03 Dec 2015 New trial record